Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPBWR1 | P48145 | 1/20 | 0.42 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | RECQL | P46063 | 1/20 | 0.38 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.38 |
| ▸ | AURKA | O14965 | 1/20 | 0.38 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.38 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.38 |
| ▸ | GSK3A | P49840 | 1/20 | 0.38 |
| ▸ | LIMK1 | P53667 | 1/20 | 0.38 |
| ▸ | IKBKE | Q14164 | 1/20 | 0.38 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.38 |
| ▸ | TAOK1 | Q7L7X3 | 1/20 | 0.38 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.38 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.38 |
| ▸ | GRIN1 | Q05586 | 3/20 | 0.38 |
| ▸ | GRIN2B | Q13224 | 3/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3321752 | 0.80 | ALDH1A1 (0.50) | ALDH1A1MAPTSMN1; SMN2RECQLCHEK1 | |
| SCHEMBL3379473 | 0.80 | GLS (0.55) | NPBWR1CYP19A1ALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL17044150 | 0.78 | CYP1A2 (0.46) | NPBWR1CYP19A1ALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL870390 | 0.76 | RECQL (0.66) | ALDH1A1MAPTSMN1; SMN2CYP1A2RECQL | |
| SCHEMBL29992643 | 0.76 | RECQL (0.66) | ALDH1A1MAPTSMN1; SMN2CYP1A2RECQL | |
| SCHEMBL4201771 | 0.76 | ALDH1A1 (0.48) | CYP19A1ALDH1A1MAPTSMN1; SMN2NOX4 | |
| SCHEMBL17044140 | 0.75 | ALDH1A1 (0.44) | NPBWR1CYP19A1ALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL3321530 | 0.75 | PKM (0.42) | ALDH1A1MAPTRECQLCHEK1AURKA | |
| SCHEMBL17458868 | 0.73 | NPBWR1 (0.47) | NPBWR1CYP19A1ALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL938232 | 0.72 | ERBB2 (0.53) | RECQLCHEK1AURKADAPK3CSNK1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1928861-B1 | 4- (IH-INDAZOL-5-YL-AMINO)-QUINAZOLINE COMPOUNDS AS ERBB RECEPTOR TYROSINE KINASE INHIBITORS FOR THE TREATMENT OF CANCER | ASTRAZENECA AB (SE) | 2010-11-17 | — | — | EP | disclosed |
| US-7820683-B2 | 4-(1H-indazol-5-yl-amino)-quinazoline compounds as erbB receptor tyrosine kinase inhibitors for the treatment of cancer | ASTRAZENECA AB (SE) | 2010-10-26 | — | — | US | disclosed |
| US-20090048251-A1 | 4-(1H-INDAZOL-5-YL-AMINO)-QUINAZOLINE COMPOUNDS AS ERBB RECEPTOR TYROSINE KINASE INHIBITORS FOR THE TREATMENT OF CANCER | ASTRAZENECA AB (SE) | 2009-02-19 | — | — | US | disclosed |
| CN-101273033-A | 4- (iH-indazol-s-yl-amino)-quinazoline compounds as ERBB receptor tyrosine kinase inhibitors for the treatment of cancer | ASTRAZENECA AB (SE) | 2008-09-24 | — | — | CN | disclosed |
| EP-1928861-A1 | 4- (IH-INDAZOL-S-YL-AMINO)-QUINAZOLINE COMPOUNDS AS ERBB RECEPTOR TYROSINE KINASE INHIBITORS FOR THE TREATMENT OF CANCER | AstraZeneca AB (SE) | 2008-06-11 | — | — | EP | disclosed |
| WO-2007034144-A1 | 4- (IH-INDAZOL-S-YL-AMINO)-QUINAZOLINE COMPOUNDS AS ERBB RECEPTOR TYROSINE KINASE INHIBITORS FOR THE TREATMENT OF CANCER | ASTRAZENECA AB (SE) | 2007-03-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090048251-A1 | 4-(1H-INDAZOL-5-YL-AMINO)-QUINAZOLINE COMPOUNDS AS ERBB RECEPTOR TYROSINE KINASE INHIBITORS FOR THE TREATMENT OF CANCER | ERBB2, ERBB4, ERBB3 | NPBWR1 1926/4885CYP19A1 1620/4885ALDH1A1 1702/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.